Insider Transactions for AN2 Therapeutics, Inc.

On September 3, 2026, and September 8, 2026, Robin Shane Readnour, a director at AN2 Therapeutics, Inc., reported the sale of Common Stock through Rule 10b5-1 trading plans adopted by MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP. The sales occurred automatically, with transactions on September 3rd totaling 6,000 shares (2,877 shares from MGC 2018 LP and 3,223 shares from MGC 2018 QP) at a weighted average price of $6.0698. On September 8th, an additional 10,019 shares were sold (4,725 shares from MGC 2018 LP and 5,294 shares from MGC 2018 QP) at a weighted average price of $6.0183. These sales were executed by MGC Venture Partners 2018 GP, LLC, the general partner of the funds. Readnour, a member of the board and a managing partner of the general partner, disclaims beneficial ownership except to the extent of pecuniary interest. Following these transactions, 9,077 shares of Common Stock are held directly.